Literature DB >> 35756948

Immunological considerations-HLA matching and management of high immunological risk recipients.

Olga Timofeeva1, James Brown2.   

Abstract

Lung transplant outcomes remain inferior largely due to mismatching in human leukocyte antigens (HLAs) that leads to chronic rejection and chronic allograft dysfunction. The mismatched donor HLAs can be recognized by the effector T cells or donor-specific HLA antibodies. This review summarizes mechanisms leading to immune responses as a result of HLA mismatching. It specifically focuses on sensitized lung transplant candidates with preformed anti-HLA antibodies, which represent a significant management challenge for physicians. In this review, we describe the diagnostic histocompatibility testing and therapeutic options for managing the sensitized lung transplant patients and discuss how multidisciplinary approach may help to improve lung transplantation outcomes. © Indian Association of Cardiovascular-Thoracic Surgeons 2021.

Entities:  

Keywords:  Desensitization; HLA matching; Histocompatibility testing; Lung transplant

Year:  2021        PMID: 35756948      PMCID: PMC9226257          DOI: 10.1007/s12055-021-01201-5

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN: 0970-9134


  56 in total

Review 1.  Antibody mediated rejection: update 2006.

Authors:  Paul Terasaki; Kazuo Mizutani
Journal:  Clin J Am Soc Nephrol       Date:  2006-04-12       Impact factor: 8.237

Review 2.  The importance of the indirect pathway of allorecognition in clinical transplantation.

Authors:  M Refik Gökmen; Giovanna Lombardi; Robert I Lechler
Journal:  Curr Opin Immunol       Date:  2008-08-04       Impact factor: 7.486

Review 3.  Advances in the understanding of the mechanism of action of IVIg.

Authors:  Hans-Peter Hartung
Journal:  J Neurol       Date:  2008-07       Impact factor: 4.849

4.  Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings.

Authors:  Mario B Regazzi; Isabella Iacona; Maria Antonietta Avanzini; Luca Arcaini; Gianpaolo Merlini; Vittorio Perfetti; Francesco Zaja; Michela Montagna; Enrica Morra; Mario Lazzarino
Journal:  Ther Drug Monit       Date:  2005-12       Impact factor: 3.681

Review 5.  IVIG-mediated effector functions in autoimmune and inflammatory diseases.

Authors:  Caroline Galeotti; Srini V Kaveri; Jagadeesh Bayry
Journal:  Int Immunol       Date:  2017-12-30       Impact factor: 4.823

Review 6.  The collaborative transplant study registry.

Authors:  Gerhard Opelz; Bernd Döhler; Andrea Ruhenstroth; Sofia Cinca; Christian Unterrainer; Lilli Stricker; Sabine Scherer; Petra Gombos; Caner Süsal; Volker Daniel; Hien Tran
Journal:  Transplant Rev (Orlando)       Date:  2013-03-05       Impact factor: 3.943

7.  Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens.

Authors:  Nancy L Reinsmoen; Jignesh Patel; James Mirocha; Chih-hung Lai; Mehrnoush Naim; Geraldine Ong; Qi Wang; Xiaohai Zhang; Frank Liou; Zhe Yu; Jon Kobashigawa
Journal:  J Heart Lung Transplant       Date:  2015-10-23       Impact factor: 10.247

8.  Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help.

Authors:  S Heidt; D L Roelen; C Eijsink; M Eikmans; C van Kooten; F H J Claas; A Mulder
Journal:  Clin Exp Immunol       Date:  2009-11-18       Impact factor: 4.330

9.  Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management.

Authors:  K Bando; I L Paradis; S Similo; H Konishi; K Komatsu; T G Zullo; S A Yousem; J M Close; A Zeevi; R J Duquesnoy
Journal:  J Thorac Cardiovasc Surg       Date:  1995-07       Impact factor: 5.209

10.  cPRA Increases With DQA, DPA, and DPB Unacceptable Antigens in the Canadian cPRA Calculator.

Authors:  K J Tinckam; R Liwski; D Pochinco; M Mousseau; A Grattan; P Nickerson; P Campbell
Journal:  Am J Transplant       Date:  2015-06-16       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.